- INVO Fertility (IVF, Financial) enhances INVOcell technology with expanded training and improved pricing.
- INVOcell achieves comparable pregnancy rates to traditional IVF, recently secured a new U.S. patent.
- INVOcell offers increased accessibility and efficiency for diverse family structures and fertility clinics.
INVO Fertility, Inc. (NASDAQ: IVF) has announced strategic enhancements to its INVOcell® technology program. These enhancements include expanded clinical training support and a more favorable pricing structure, aiming to increase accessibility and affordability for patients undergoing fertility treatments. The INVOcell system, which is the first FDA-cleared intravaginal culture (IVC) system, provides a more natural alternative to traditional in vitro fertilization (IVF) with pregnancy rates comparable to conventional methods.
As part of its ongoing efforts to strengthen its position in the fertility industry, INVO Fertility focuses on both technological innovation and fertility clinic operations. The INVOcell technology utilizes a woman's body as a natural incubator, which not only offers a more intimate and less laboratory-intensive process but also maintains success rates parallel to conventional IVF.
INVO Fertility highlights several benefits of the INVOcell system, including increased accessibility for diverse family structures—such as same-sex couples and single parents—and operational efficiency for fertility clinics. With the recent U.S. patent approval, clinics using INVOcell can expect improved workflow and the ability to accommodate more patients within existing infrastructure.
To further support the adoption of INVOcell, INVO Fertility provides comprehensive training and clinical support for embryologists and physicians. This is complemented by educational campaigns to increase awareness of the INVOcell system's effectiveness, as evidenced by clinical studies and real-world outcomes.
INVO Fertility CEO, Steve Shum, emphasized the company's commitment to democratizing fertility care, stating, "INVOcell represents a unique and innovative technology that allows us to provide high-quality, affordable care while empowering physicians with cutting-edge solutions." The company's initiatives align with its mission to make fertility treatments more accessible to a wider range of patients.
